Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule

Cancer Research

Volumn 61, Issue 12, 2001, Pages 4761-4765

  Trojan, Andreas ^a,b   Witzens, Mathias ^a   Schultze, Joachim L ^a   Vonderheide, Robert H ^a   Harig, Sabine ^a   Krackhardt, Angela M ^a   Stahel, Rolf A ^b   Gribben, John G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL CULTURE;

ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; LUNG NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035874893     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Human tumor antigens recognized by T lymphocytes
2. Human neoplasms elicit multiple specific immune responses in the autologous host
3. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
4. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
5. The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects
6. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer
7. Peptides naturally presented by MHC class I molecules
8. SYFPEITHI: Database for MHC ligands and peptide motifs
9. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
10. Chimeric peptides: A new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: Application in antiviral vaccination
11. Immunoglobulin framework derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
12. Heteroclitic immunization induces tumor immunity
13. A single amino acid substitution in an MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes
14. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
15. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
16. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
17. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
18. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
19. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
20. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
21. Identification of HLA-A2-restricted T-cell epitopes derived from the MUCI tumor antigen for broadly applicable vaccine therapies
22. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
23. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2
24. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
25. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2
26. The structural analysis of adhesions mediated by Ep-CAM
27. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells
28. The biology of the 17-1A antigen (Ep-CAM)
29. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
30. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
31. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer
32. Identification of potential HLA-A*0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA)
33. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer
34. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2
35. MHC ligands and peptide motifs: First listing
36. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
37. Inducing autoimmune disease to treat cancer
38. Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: An investigation of human cancers transplanted into severe combined immunodeficient mice
39. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments
40. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation
41. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors
42. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer
43. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCASI